• Explore /
  • Poster
  • / STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.

STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Abstract Poster

Authors

Samuel Klempner

Samuel J Klempner

Mass General Cancer Center, Boston, MA

Samuel J Klempner , Kohei Shitara , Allan Sison , Jennifer Scott , Dana Wishengrad , Jack Ronayne , Joon Rhee , Siddhartha Mitra , Dimitry S. A. Nuyten , Yelena Y. Janjigian , Zev A. Wainberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT05568095

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4206)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4206

Abstract #

TPS4206

Poster Bd #

509b

Abstract Disclosures

Similar Posters

First Author: Yelena Yuriy Janjigian

First Author: Haeseong Park

First Author: Manish A. Shah

First Author: Nataliya Volodymyrivna Uboha